NF546
NF546 is a selective non-nucleotide P2Y11 agonist with a pEC50 of 6.27. NF546 stimulates release of interleukin-8 from human monocyte-derived dendritic cells.
For research use only. We do not sell to patients.
- CAS No.: 1006028-37-0
- Formula: C47H44N6Na4O17P4
- Molecular Weight:1180.74
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-10064
TicagrelorP2Y12 Antagonist -
HY-15284A
Prasugrel hydrochlorideP2Y12 Receptor Antagonist -
HY-108658
MRS2500 tetraammoniumP2Y1 Receptor Antagonist -
HY-108660
PSB-0739P2Y12 Receptor Antagonist -
HY-13104
MRS 2578Apoptosis Inducer -
HY-15799
AZD1283P2Y12 Receptor Antagonist -
HY-W010832
Uridine-5'-diphosphate disodium saltNucleotide -
HY-15283
ClopidogrelAntiplatelet Agent -
HY-108648
2-MeS-ADP trisodiumP2Y Receptor Agonist -
HY-108662
PITP2Y1 Receptor Antagonist -
HY-111557
YM-254890Gαq/11 Selective Inhibitor -
HY-18775
N6-(4-Hydroxybenzyl)adenosineENT1 Inhibitor/A2aR Agonist
All P2Y Receptor Isoforms
More
Biological Activity
Description
IC50 & Target
pEC50: 6.27 (P2Y11)[1]
In Vitro
NF546 is relatively selective for P2Y11 over P2Y1, P2Y2, P2Y4, P2Y6, P2Y12, P2X1, P2X2, and P2X2-X3. NF546 (100 μM; 24 hours) is equi-efficacious in stimulating TSP-1 release and inhibiting the LPS-induced release of IL-12p70 in human monocyte-derived dendritic cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 1006028-37-0
-
Molecular Weight 1180.74
-
Formula C47H44N6Na4O17P4
-
SMILES
O=P(O)(O[Na])CC1=C(C=CC(CP(O)(O[Na])=O)=C1)NC(C2=CC(NC(C3=CC(NC(NC4=CC(C(NC5=CC(C(NC6=C(C=C(CP(O)(O[Na])=O)C=C6)CP(O)(O[Na])=O)=O)=CC=C5C)=O)=CC=C4)=O)=CC=C3)=O)=C(C)C=C2)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Monocyte-derived dendritic cell differentiation
Human monocyte-derived dendritic cells are generated by isolating PBMC-derived monocytes and culturing them with GM-CSF plus IL-4, which produces cells with dendritic-cell antigen-presenting properties, reduced monocyte phenotype, and increased dendritic-cell functional readouts such as antigen uptake, allogeneic T-cell stimulation, and expression of markers including HLA-DR, CD80, CD86, CD83, CD1a, or CD209 depending on protocol and maturation state. The main readout is phenotypic and functional differentiation: immature MoDCs are commonly evaluated by loss or reduction of CD14 with acquisition of dendritic-cell markers and antigen uptake capacity, whereas mature MoDCs are evaluated by increased CD83, CD80, CD86, HLA-DR, and T-cell stimulatory function after exposure to maturation stimuli such as TNF-α or a cytokine/PGE2 cocktail.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
NF546 Related Classifications
HY-108661 Related Classifications
Powered by Bioz